6533b83afe1ef96bd12a6fa7

RESEARCH PRODUCT

DNA methylation profiling to explore colorectal tumor differences according to menopausal hormone therapy use in women

Dominic EdelmannKatja ButterbachHendrik BläkerWilfried RothAxel BennerMichael HoffmeisterHermann BrennerBarbara BurwinkelBarbara BurwinkelEsther HerpelOdilia PopandaPeter SchmezerSonja NeumeyerSonja NeumeyerCsaba TothJenny Chang-claudeJenny Chang-claudeCornelia Jäkel

subject

Cancer Researchmedicine.drug_classColorectal cancermedicine.medical_treatmentEstrogen receptorBiologychemistry.chemical_compoundGeneticsmedicineEstrogen Receptor betaHumansGeneAgedAged 80 and overEstrogen Replacement TherapyHormone replacement therapy (menopause)DNA MethylationMiddle Agedmedicine.diseasechemistryCpG siteEstrogenDNA methylationCancer researchCpG IslandsFemaleMenopauseColorectal NeoplasmsDNA

description

Aim: Use of menopausal hormone therapy (MHT) has been associated with a reduced risk for colorectal cancer, but mechanisms underlying this relationship are not well understood. In the colon, MHT appears to act through estrogen receptor β (ERβ) which may influence DNA methylation by binding to DNA. Using genome-wide methylation profiling data, we aimed to identify genes that may be differentially methylated according to MHT use. Materials & methods: DNA methylation was measured using Illumina HumanMethylation450k arrays in two independent tumor sample sets of colorectal cancer patients. Differential methylation was determined using R/limma. Results: In the discovery analysis, two CpG sites showed differential DNA methylation according to MHT use, both were not replicated. In stratified analyses, 342 CpG sites were associated with current MHT use only in ERβ-positive tumors. Conclusion: The suggestive findings of differential methylation according to current MHT use in ERβ-positive tumors warrant further investigation.

yearjournalcountryeditionlanguage
2019-11-23Epigenomics
https://doi.org/10.2217/epi-2019-0051